76 related articles for article (PubMed ID: 16734253)
1. [Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer].
Ghezala W; Lefi M; Touffahi M; Saïdi R; Farhane S; Saad H
Prog Urol; 2006 Apr; 16(2):225. PubMed ID: 16734253
[No Abstract] [Full Text] [Related]
2. [Molecular pathways of tumour angiogenesis and new targeted therapeutic approaches in renal cancer].
Fergelot P; Rioux-Leclercq N; Patard JJ
Prog Urol; 2005 Dec; 15(6):1021-9. PubMed ID: 16429647
[TBL] [Abstract][Full Text] [Related]
3. [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma].
Bartsch G; Eggert K; Soker S; Fiedler W; Laack E; Volkmer BG; Gschwend J; Bokemeyer C; Hautmann R; Schuch G
Urologe A; 2007 Sep; 46(9):1289-90. PubMed ID: 17624513
[No Abstract] [Full Text] [Related]
4. Interview with professor Per-Anders Abrahamson: angiogenesis and renal cell carcinoma.
Abrahamson PA
Eur Urol; 2006 Sep; 50(3):609-11. PubMed ID: 16824676
[No Abstract] [Full Text] [Related]
5. Angiogenesis inhibition in non-clear cell renal cancer.
Stadler W
Clin Adv Hematol Oncol; 2008 Jul; 6(7):507-9. PubMed ID: 18654117
[No Abstract] [Full Text] [Related]
6. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
[TBL] [Abstract][Full Text] [Related]
7. [Angiogenesis: the renal cancer model].
Méjean A; Lebret T
Prog Urol; 2008 Nov; 18 Suppl 7():S309-14. PubMed ID: 19070808
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis: an organizing principle for drug discovery?
Folkman J
Nat Rev Drug Discov; 2007 Apr; 6(4):273-86. PubMed ID: 17396134
[TBL] [Abstract][Full Text] [Related]
9. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts.
Yalcin M; Bharali DJ; Lansing L; Dyskin E; Mousa SS; Hercbergs A; Davis FB; Davis PJ; Mousa SA
Anticancer Res; 2009 Oct; 29(10):3825-31. PubMed ID: 19846915
[TBL] [Abstract][Full Text] [Related]
10. Complexity of tumor vasculature in clear cell renal cell carcinoma.
Qian CN; Huang D; Wondergem B; Teh BT
Cancer; 2009 May; 115(10 Suppl):2282-9. PubMed ID: 19402071
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus for advanced renal cell carcinoma.
Figlin RA
Clin Adv Hematol Oncol; 2007 Nov; 5(11):893. PubMed ID: 18185488
[No Abstract] [Full Text] [Related]
12. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
Kong D; Okamura M; Yoshimi H; Yamori T
Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
[TBL] [Abstract][Full Text] [Related]
13. [The actual place of anti-angiogenesis in non-small cell lung cancer].
Mennecier B
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S198-205. PubMed ID: 18235414
[TBL] [Abstract][Full Text] [Related]
14. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
[TBL] [Abstract][Full Text] [Related]
15. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
Roy V; Perez EA
Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790
[TBL] [Abstract][Full Text] [Related]
16. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches.
Dumont F; Altmeyer A; Bischoff P
Expert Opin Ther Pat; 2009 Jun; 19(6):775-99. PubMed ID: 19456277
[TBL] [Abstract][Full Text] [Related]
19. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.
Rosen MA; Schnall MD
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):770s-776s. PubMed ID: 17255308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
